Clinical Studies:

EVEREST STUDY

Summarized by Lauren Kiryakoza, MD (Bascom Palmer Eye Institute)

Citation: Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464. doi:10.1097/IAE.0b013e31824f91e8 PMID: 22426346

Key Points

  • EVEREST was a multicenter (Asia), double-masked, randomized controlled trial examining efficacy of standard fluence verteporfin photodynamic therapy (PDT) + ranibizumab (0.5mg), verteporfin PDT monotherapy, or ranibizumab monotherapy in treatment of symptomatic macular polypoidal choroidal vasculopathy (PCV) in treatment naïve patients ≥18 years of age.
  • The primary endpoint was proportion of patients with complete regression of polyps assessed by indocyanine green angiography (ICGA) at 6 months.
  • Results demonstrated superiority of verteporfin PDT + ranibizumab and verteporfin PDT monotherapy compared to ranibizumab monotherapy (77.8% and 71.4% vs. 28.6% P <0.01) in achieving the primary endpoint.

STUDY DESIGN


STUDY OBJECTIVES and ENDPOINTS


RANDOMIZATION SCHEME AND INTERVENTIONS


STUDY SUBJECTS


STUDY EYE INCLUSION CRITERIA


TREATMENT


ASSESSMENT METHODS


RESULTS

Polyp regression


Polyp area


Best-Corrected Visual Acuity


Central Retinal Thickness


Fluorescein Angiography Assessment of Leakage


CONCLUSIONS